87/100
✓ Peer-reviewed
alzhub usefulness score 87 out of 100.
·
Diabetes care
·
2015-12-17
Study-level data from 14 studies, 2,310,330 individuals, and 102,174 dementia case patients were included. 3 key findings →
Design: meta-analysis
Participants: 2,310,330
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
The 172 total participants had a mean (SD) age of 75.7 (4.8) years, and 108 (62.8%) were women. 4 key findings →
Participants: 172
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
79/100
✓ Peer-reviewed
alzhub usefulness score 79 out of 100.
·
JAMA neurology
·
2022-06-01
The findings suggest that risk factors associated with ADRDs have changed over the past decade and differ based on sex and race and ethnicity. 5 key findings →
Design: meta-analysis
Participants: 378
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
77/100
✓ Peer-reviewed
alzhub usefulness score 77 out of 100.
·
PLoS medicine
·
2019-07-23
With no effective treatments for cognitive decline or dementia, improving the evidence base for modifiable risk factors is a research priority. 1 key finding →
Design: meta-analysis
Participants: 48,522
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
75/100
✓ Peer-reviewed
alzhub usefulness score 75 out of 100.
·
JAMA network open
·
2021-02-01
Among 34 349 participants, 26 088 who self-reported Black or White race, were free of stroke and dementia, and had covariate data at or before the first cognitive assessment were included for analysis. 2 key findings →
Design: cohort study
Participants: 349
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Patients with MCI with APOEε4, abnormal CSF τ level, hippocampal and medial temporal lobe atrophy, entorhinal atrophy, depression, diabetes, hypertension, older age, female gender, lower MMSE score and higher ADAS-cog score, had a high risk for the progression to AD. 1 key finding →
Design: meta-analysis
Participants: 14,821
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Frontotemporal lobar degeneration with neuronal inclusions of the TAR DNA-binding protein 43 (FTLD-TDP) is a fatal neurodegenerative disorder with only a limited number of risk loci identified. 3 key findings →
Design: meta-analysis
Participants: 985
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
74/100
✓ Peer-reviewed
alzhub usefulness score 74 out of 100.
·
JAMA
·
2022-04-01
Dementia is a significant public health challenge and may have greater incidence among older adults from underrepresented racial and ethnic minority groups. 4 key findings →
Design: cohort study
Participants: 90
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
72/100
✓ Peer-reviewed
alzhub usefulness score 72 out of 100.
·
JAMA neurology
·
2014-12-01
Of these, 4361 (8.4%) developed dementia compared with 6610 patients with NTT (5.9%) (P Conclusions and relevance Among patients evaluated in the ED or inpatient settings, those with moderate to severe TBI at 55 years or older or mild TBI at 65 years or older had an increased risk of developing dementia. 3 key findings →
Design: cohort study
Participants: 164,661
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
The number of years of formal education completed by individuals is positively correlated with their cognitive function throughout adulthood and predicts lower risk of dementia late in life. 4 key findings →
Design: meta-analysis
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
71/100
✓ Peer-reviewed
alzhub usefulness score 71 out of 100.
·
JAMA network open
·
2026-03-02
Across the cohorts, each 10-year increase in BAI was associated with a 39% higher risk of incident dementia (hazard ratio [HR], 1.39 [95% CI, 1.21-1.59]; P Conclusions and relevance In this IPD meta-analysis, a higher sleep EEG-based BAI was associated with a higher risk of incident dementia. 3 key findings →
Design: meta-analysis
Participants: 7,105
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
71/100
✓ Peer-reviewed
alzhub usefulness score 71 out of 100.
·
Neurology
·
2018-04-18
Among military veterans, mTBI is associated with 56% increased risk of PD, even after adjusting for demographics and medical/psychiatric comorbidities. 4 key findings →
Design: cohort study
Participants: 325,870
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
70/100
✓ Peer-reviewed
alzhub usefulness score 70 out of 100.
·
JAMA neurology
·
2018-09-01
In this cohort study of more than 350 000 veterans, even mild TBI without LOC was associated with more than a 2-fold increase in the risk of dementia diagnosis. 3 key findings →
Design: cohort study
Participants: 178
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
69/100
✓ Peer-reviewed
alzhub usefulness score 69 out of 100.
·
JAMA psychiatry
·
2016-05-01
The analytic cohort included 2488 black and white older adults with repeated depressive symptom assessments from baseline to year 5 who were free of dementia throughout that period. 4 key findings →
Design: prospective cohort
Participants: 1,322
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
69/100
✓ Peer-reviewed
alzhub usefulness score 69 out of 100.
·
JAMA neurology
·
2023-09-01
Among the 1 637 484 Veterans Health Administration patients, the mean (SD) age was 68.6 (7.7) years, and 1 604 677 (98.0%) were men. 5 key findings →
Design: cohort study
Participants: 7,318
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Over follow-up, 449 (18.3%) participants developed dementia. 2 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
67/100
✓ Peer-reviewed
alzhub usefulness score 67 out of 100.
·
JAMA neurology
·
2020-07-01
Among 34 349 participants, 19 378 individuals who were free of stroke and dementia and had longitudinal BP, cognitive, and covariate data were included in the analysis. 2 key findings →
Design: longitudinal study
Participants: 349
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
67/100
✓ Peer-reviewed
alzhub usefulness score 67 out of 100.
·
JAMA Network Open
·
2024-12-12
The study consisted of 20 400 patients (9264 female [45.4%]; 1576 Black [7.7%], 3944 Latinx [19.3%], and 10 480 White [51.4%]), including 5100 patients with mTBI (median [IQR] age, 36.0 [25.0-51.0] years), 5100 patients with msTBI (median [IQR age, 35.0 [25.0-52.0] years), and 10 200 matched patients in the control group (median [IQR] age, 36.0 [25.0-51.0] years). 5 key findings →
Design: cohort study
Participants: 400
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
Neurology
·
2025-06-27
Among eligible participants (n = 705,061), 264,294 individuals (37.5% of eligible participants) initiated any statin during 2001-2010 ("initiators"), of whom 249,613 (94.4%) were matched with 255,937 unique noninitiators to create the analytic sample (322,358 unique participants; mean age at baseline = 67.4 years; 55.1% female). 3 key findings →
Design: cohort
Participants: 322,358
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Among well-functioning older adults, DM and poor glucose control among those with DM are associated with worse cognitive function and greater decline. 5 key findings →
Design: cohort study
Participants: 717
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
65/100
✓ Peer-reviewed
alzhub usefulness score 65 out of 100.
·
JAMA Network Open
·
2023-10-02
In this study, terminating metformin treatment was associated with increased dementia incidence. 5 key findings →
Design: cohort
Participants: 41,346
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
65/100
✓ Peer-reviewed
alzhub usefulness score 65 out of 100.
·
JAMA Network Open
·
2024-07-01
In this cohort and MR study of UK Biobank participants, cataracts were associated with increased risk of dementia, especially vascular dementia, and reduced total brain volumes. 5 key findings →
Design: cohort
Participants: 304,953
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Female participants had a lower hazard of early-onset dementia compared with males (HR 0·70 [95% CI 0·61-0·80]). 4 key findings →
Design: cohort
Participants: 544,442
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Older, healthy women with decreased circadian activity rhythm amplitude and robustness, and delayed rhythms have increased odds of developing dementia and MCI. 3 key findings →
Design: cross-sectional
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
64/100
✓ Peer-reviewed
alzhub usefulness score 64 out of 100.
·
PLoS medicine
·
2017-03-28
Secondary analysis suggested that this effect may be driven primarily by individuals who are negative for the established AD genetic risk factor, apolipoprotein E (APOE) ɛ4. 5 key findings →
Design: case-control study
Participants: 346
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomized / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multicenter collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 32,180 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.